1. Home
  2. ORKA
  3. ORKA News

Latest Oruka Therapeutics Inc. Common Stock (ORKA) News on January 19, 2025

Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001
ORKA

TipRanks

a month ago

Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
ORKA

GlobeNewswire

a month ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
ORKA

GlobeNewswire

a month ago

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15%
ORKA

Simply Wall St.

a month ago

Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15%

Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
ORKA

GlobeNewswire

2 months ago

Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
ORKA

GlobeNewswire

2 months ago

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Multiple November Investor Conferences
ORKA

GlobeNewswire

2 months ago

Oruka Therapeutics to Present at Multiple November Investor Conferences

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
ORKA

GlobeNewswire

4 months ago

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Oruka Therapeutics Announces $200 Million Private Placement
ORKA

GlobeNewswire

4 months ago

Oruka Therapeutics Announces $200 Million Private Placement

Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
ORKA

GlobeNewswire

4 months ago

Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19

Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
ORKA

GlobeNewswire

5 months ago

Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million

Share on Social Networks: